Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...
Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Danish drugmaker Novo Nordisk and Eli Lilly currently dominate the market for weight-loss treatments with their injectable drugs. Novo is studying the pill version of its experimental drug ...
Danish drugmaker Novo Nordisk and Eli Lilly currently dominate the market for weight-loss treatments with their injectable drugs. Novo is studying the pill version of its experimental drug, amycretin, ...
Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results